Search

Your search keyword '"Fang, Weijia"' showing total 420 results
Start Over Author "Fang, Weijia"
420 results on '"Fang, Weijia"'

51. Data from Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing–Assisted Multiomics Analysis

Author

Bao, Xuanwen, primary, Li, Qiong, primary, Chen, Jinzhang, primary, Chen, Diyu, primary, Ye, Chanqi, primary, Dai, Xiaomeng, primary, Wang, Yanfang, primary, Li, Xin, primary, Rong, Xiaoxiang, primary, Cheng, Fei, primary, Jiang, Ming, primary, Zhu, Zheng, primary, Ding, Yongfeng, primary, Sun, Rui, primary, Liu, Chuan, primary, Huang, Lingling, primary, Jin, Yuzhi, primary, Li, Bin, primary, Lu, Juan, primary, Wu, Wei, primary, Guo, Yixuan, primary, Fu, Wenguang, primary, Langley, Sarah Raye, primary, Tano, Vincent, primary, Fang, Weijia, primary, Guo, Tiannan, primary, Sheng, Jianpeng, primary, Zhao, Peng, primary, and Ruan, Jian, primary

Published
2023
Full Text
View/download PDF

52. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

Author

Qin, Shukui, primary, Chen, Zhendong, additional, Fang, Weijia, additional, Ren, Zhenggang, additional, Xu, Ruocai, additional, Ryoo, Baek-Yeol, additional, Meng, Zhiqiang, additional, Bai, Yuxian, additional, Chen, Xiaoming, additional, Liu, Xiufeng, additional, Xiao, Juxiang, additional, Ho, Gwo Fuang, additional, Mao, Yimin, additional, Wang, Xin, additional, Ying, Jieer, additional, Li, Jianfeng, additional, Zhong, Wenyan, additional, Zhou, Yu, additional, Siegel, Abby B., additional, and Hao, Chunyi, additional

Published
2023
Full Text
View/download PDF

53. Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial

Author

Ren, Zhenggang, Ducreux, Michel, Abou-Alfa, Ghassan K., Merle, Philippe, Fang, Weijia, Edeline, Julien, Li, Zhiwei, Wu, Lihua, Assenat, Eric, Hu, Sheng, Rimassa, Lorenza, Zhang, Tao, Blanc, Jean-Frédéric, Pan, Hongming, Ross, Paul, Yen, Chia-Jui, Tran, Albert, Shao, Guoliang, Bouattour, Mohamed, Chen, Yajin, Meyer, Tim, Hou, Jinlin, Tougeron, David, Bai, Yuxian, Hou, Ming-Mo, Meng, Zhiqiang, Wu, John, Li, Vincent, Chica-Duque, Sandra, and Cheng, Ann-Lii

Abstract

Introduction:Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of tislelizumab in patients with previously treated advanced HCC. Methods:The multiregional phase 2 study RATIONALE-208 examined single-agent tislelizumab (200 mg intravenously every 3 weeks) in patients with advanced HCC with Child-Pugh A, Barcelona Clinic Liver Cancer stage B or C, and who had received one or more prior lines of systemic therapy. The primary endpoint was objective response rate (ORR), radiologically confirmed per Response Evaluation Criteria in Solid Tumors version 1.1 by the Independent Review Committee. Safety was assessed in patients who received ≥1 dose of tislelizumab. Results:Between April 9, 2018, and February 27, 2019, 249 eligible patients were enrolled and treated. After a median study follow-up of 12.7 months, ORR was 13% (n= 32/249; 95% confidence interval [CI], 9–18), including five complete and 27 partial responses. The number of prior lines of therapy did not impact ORR (one prior line, 13% [95% CI, 8–20]; two or more prior lines, 13% [95% CI, 7–20]). Median duration of response was not reached. The disease control rate was 53%, and median overall survival was 13.2 months. Of the 249 total patients, grade ≥3 treatment-related adverse events were reported in 38 (15%) patients; the most common was liver transaminase elevations in 10 (4%) patients. Treatment-related adverse events led to treatment discontinuation in 13 (5%) patients or dose delay in 46 (19%) patients. No deaths were attributed to the treatment per investigator assessment. Conclusion:Tislelizumab demonstrated durable objective responses, regardless of the number of prior lines of therapy, and acceptable tolerability in patients with previously treated advanced HCC.

Published
2023
Full Text
View/download PDF

56. Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)

Author

Li, Jian, Yuan, Ying, Yang, Fan, Wang, Yi, Zhu, Xu, Wang, Zhenghang, Zheng, Shu, Wan, Desen, He, Jie, Wang, Jianping, Ba, Yi, Bai, Chunmei, Bai, Li, Bai, Wei, Bi, Feng, Cai, Kaican, Cai, Muyan, Cai, Sanjun, Chen, Gong, Chen, Keneng, Chen, Lin, Chen, Pengju, Chi, Pan, Dai, Guanghai, Deng, Yanhong, Ding, Kefeng, Fan, Qingxia, Fang, Weijia, Fang, Xuedong, Feng, Fengyi, Fu, Chuangang, Fu, Qihan, Gu, Yanhong, He, Yulong, Jia, Baoqing, Jiang, Kewei, Lai, Maode, Lan, Ping, Li, Enxiao, Li, Dechuan, Li, Jin, Li, Leping, Li, Ming, Li, Shaolei, Li, Yexiong, Li, Yongheng, Li, Zhongwu, Liang, Xiaobo, Liang, Zhiyong, Lin, Feng, Lin, Guole, Liu, Hongjun, Liu, Jianzhong, Liu, Tianshu, Liu, Yunpeng, Pan, Hongming, Pan, Zhizhong, Pei, Haiping, Qiu, Meng, Qu, Xiujuan, Ren, Li, Shen, Zhanlong, Sheng, Weiqi, Song, Chun, Song, Lijie, Sun, Jianguo, Sun, Lingyu, Sun, Yingshi, Tang, Yuan, Tao, Min, Wang, Chang, Wang, Haijiang, Wang, Jun, Wang, Shubin, Wang, Xicheng, Wang, Xishan, Wang, Ziqiang, Wu, Aiwen, Wu, Nan, Xia, Lijian, Xiao, Yi, Xing, Baocai, Xiong, Bin, Xu, Jianmin, Xu, Jianming, Xu, Nong, Xu, Ruihua, Xu, Zhongfa, Yang, Yue, Yao, Hongwei, Ye, Yingjiang, Yu, Yonghua, Yu, Yueming, Yue, Jinbo, Zhang, Jingdong, Zhang, Jun, Zhang, Suzhan, Zhang, Wei, Zhang, Yanqiao, Zhang, Zhen, Zhang, Zhongtao, Zhao, Lin, Zhao, Ren, Zhou, Fuxiang, Zhou, Jian, Jin, Jing, Gu, Jin, and Shen, Lin

Published
2019
Full Text
View/download PDF

59. Additional file 10 of Single-cell analysis reveals HBV-specific PD-1+CD8+ TRM cells in tumor borders are associated with HBV-related hepatic damage and fibrosis in HCC patients

Author

Liu, Lulu, Liu, Junwei, Li, Pan, Luo, Jijun, Qin, Rui, Peng, Qiao, Li, Bin, Wei, Xuyong, Wang, Tian, Shi, Hongyu, Wang, Ming-Da, Li, Chao, Fang, Weijia, Chen, Wei, Xu, Xiao, Yang, Tian, Yin, Weiwei, and Zeng, Xun

Abstract

Additional file 10: FigureS3.Correlation of HBV clinical features with immune features. (A) Comparisons ofthe frequencies of major immune subsets across HBV infection and HCC tissues.(B and C) Comparisons of the frequencies of selected meta-clusters between HBV+and HBV- samples in INT (B) and TB (C) tissues. (D) The heatmap of the Spearmancorrelation coefficients between HBV clinical features and immune features inTB tissues, colored by correlation coefficients and for pairs with p-value morethan 0.1 were set to zero. E, The correlation plots between selected HBVclinical features and immune features as in (D). Two-way ANOVA test was used in(A), with *p < 0.05, **p < 0.01, and ***p < 0.001.

Published
2023
Full Text
View/download PDF

60. Additional file 8 of Single-cell analysis reveals HBV-specific PD-1+CD8+ TRM cells in tumor borders are associated with HBV-related hepatic damage and fibrosis in HCC patients

Author

Liu, Lulu, Liu, Junwei, Li, Pan, Luo, Jijun, Qin, Rui, Peng, Qiao, Li, Bin, Wei, Xuyong, Wang, Tian, Shi, Hongyu, Wang, Ming-Da, Li, Chao, Fang, Weijia, Chen, Wei, Xu, Xiao, Yang, Tian, Yin, Weiwei, and Zeng, Xun

Abstract

Additional file 8: FigureS1.CyTOF data analyses of immune cells from HCC and HH tissues.(A) Thegating strategy of CyTOF data for live and singleton immune cells. (B) The tSNEplots of selected markers as in (Figure 1B). (C) The heatmap of 100 SOMsubclusters, major immune cell subtypes, and cluster frequencies were labeledon the top.

Published
2023
Full Text
View/download PDF

61. Additional file 9 of Single-cell analysis reveals HBV-specific PD-1+CD8+ TRM cells in tumor borders are associated with HBV-related hepatic damage and fibrosis in HCC patients

Author

Liu, Lulu, Liu, Junwei, Li, Pan, Luo, Jijun, Qin, Rui, Peng, Qiao, Li, Bin, Wei, Xuyong, Wang, Tian, Shi, Hongyu, Wang, Ming-Da, Li, Chao, Fang, Weijia, Chen, Wei, Xu, Xiao, Yang, Tian, Yin, Weiwei, and Zeng, Xun

Abstract

Additional file 9: FigureS2. The clinical-related immunealterations in TB tissues. (A) Comparisons of the frequencies of selectedmeta-clusters between INT and TB tissues. (B) The heatmap of the comparisons ofmeta-cluster frequencies across patients grouped by defined clinical featuresin TB tissues, colored by the signed -log10(p-value). (C)Comparisons of the meta-cluster frequencies in TB tissues between early-stageand advanced-stage patients classified as in (B). Unpaired student’s t-test wasused in (A-C), with *p < 0.05, **p < 0.01, and ***p < 0.001.

Published
2023
Full Text
View/download PDF

62. 197 Preliminary safety and efficacy of autologous anti-MSLN T cell engager-loaded T cells (CAB-T) in patients with mesothelin-expressing advanced solid tumors

Author

Bao, Xuanwen, primary, Liu, Lulu, additional, Gu, Jialin, additional, Li, Mei, additional, Tong, Zhou, additional, Zhang, Hangyu, additional, Li, Yalin, additional, Gong, Xinjiang, additional, Wang, Peng, additional, Tsun, Andy, additional, Hu, Guoqiang, additional, Chou, Chuan-Chu, additional, Li, Zhiyuan, additional, and Fang, Weijia, additional

Published
2022
Full Text
View/download PDF

63. The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study

Author

Chen, Mifen, primary, Wang, Zhenghang, additional, Liu, Zimin, additional, Liu, Ning, additional, Fang, Weijia, additional, Zhang, Hangyu, additional, Jin, Xuan, additional, Li, Jiayi, additional, Zhao, Weifeng, additional, Qu, Huajun, additional, Song, Fanghua, additional, Chang, Zhiwei, additional, Li, Yi, additional, Tang, Yong, additional, Xu, Chunlei, additional, Zhang, Xiaotian, additional, Wang, Xicheng, additional, Peng, Zhi, additional, Cai, Jinping, additional, Li, Jian, additional, and Shen, Lin, additional

Published
2022
Full Text
View/download PDF

64. Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial

Author

Ren, Zhenggang, primary, Ducreux, Michel, additional, Abou-Alfa, Ghassan K., additional, Merle, Philippe, additional, Fang, Weijia, additional, Edeline, Julien, additional, Li, Zhiwei, additional, Wu, Lihua, additional, Assenat, Eric, additional, Hu, Sheng, additional, Rimassa, Lorenza, additional, Zhang, Tao, additional, Blanc, Jean-Frédéric, additional, Pan, Hongming, additional, Ross, Paul, additional, Yen, Chia-Jui, additional, Tran, Albert, additional, Shao, Guoliang, additional, Bouattour, Mohamed, additional, Chen, Yajin, additional, Meyer, Tim, additional, Hou, Jinlin, additional, Tougeron, David, additional, Bai, Yuxian, additional, Hou, Ming-Mo, additional, Meng, Zhiqiang, additional, Wu, John, additional, Li, Vincent, additional, Chica-Duque, Sandra, additional, and Cheng, Ann-Lii, additional

Published
2022
Full Text
View/download PDF

66. Single-cell analysis reveals HBV-specific PD-1+CD8+ TRM cells in tumor borders are associated with HBV-related hepatic damage and fibrosis in HCC patients.

Author

Liu, Lulu, Liu, Junwei, Li, Pan, Luo, Jijun, Qin, Rui, Peng, Qiao, Li, Bin, Wei, Xuyong, Wang, Tian, Shi, Hongyu, Wang, Ming-Da, Li, Chao, Fang, Weijia, Chen, Wei, Xu, Xiao, Yang, Tian, Yin, Weiwei, and Zeng, Xun

Subjects
HEPATIC fibrosis, HEPATITIS B, HEPATITIS B virus, T cells, IMMUNE checkpoint proteins
Abstract

Immune checkpoint blockade (ICB) treatment of hepatocellular carcinoma (HCC) patients with hepatitis B virus (HBV) infection may activate viral-specific T cells to attack HBV infected hepatocytes and thus induce immune-related liver injury. Therefore, it is important to deeply understand the impacts of HBV infection on HCC immune microenvironment in order to better design effective immunotherapies for HBV+ (HBV infected) HCC patients. Here, We performed cytometry by time-of-flight (CyTOF) analyses to characterize the distinct immune compositions of HCC tumors, tumor borders, and their associations with HCC/HBV related clinical characteristics. We identified 31 distinct immune clusters and found significant associations between immune signatures with clinicopathological features of HCC. We further revealed the HBV infection had more effects on shaping immune compositions in tumor borders than in tumors, with the significant enrichment of HBV-specific PD-1+CD8+ tissue-resident memory T (TRM) cells in tumor borders of HBV+ patients. We confirmed this subset with a more exhausted phenotype and respond more actively under anti-PD-L1 treatment, suggesting its involvement in immune-related liver injury induced by ICB treatment to HBV+ HCC patients. Our study shows it may be necessary to consider antiviral prophylaxis for HBV+ HCC patients receiving ICB treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

67. A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394

Author

Qin, Shukui, Fang, Weijia, Ren, Zhenggang, Ou, Shuangyan, Lim, Ho Yeong, Zhang, Feng, Lee, Kin Chung, Choi, Hye Jin, Tong, Jiandong, Tao, Min, Xu, Aibing, Cheng, Ashley, Lu, Chang-Hsien, Chiu, Chang-Fang, Wahid, Mohamed Ibrahim Abdul, Kamble, Shital, Norquist, Josephine M., Zhong, Wenyan, Li, Chen, and Chen, Zhendong

Abstract

Introduction:KEYNOTE-394 showed pembrolizumab significantly improved overall survival, progression-free survival, and objective response rate with manageable safety versus placebo for patients from Asia with previously treated advanced hepatocellular carcinoma. We present results on health-related quality of life (HRQoL). Methods:HRQoL was evaluated using the EORTC Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and EuroQol-5D-3L (EQ-5D-3L) questionnaires. Key HRQoL endpoints were least squares mean (LSM) score changes from baseline to week 12 and time to deterioration (TTD) for EORTC QLQ-C30 global health status (GHS)/QoL. pvalues were one-sided and nominal without adjustment for multiplicity. Results:The HRQoL population included patients randomly assigned to pembrolizumab (n =298) and placebo (n =152). From baseline to week 12, a greater decline in EORTC QLQ-C30 GHS/QoL score was observed with placebo (LSM, −8.4; 95% CI: −11.7 to −5.1) versus pembrolizumab (−4.0; 95% CI: −6.4 to −1.6; difference vs. placebo: 4.4; 95% CI: 0.5–8.4; nominal p= 0.0142). Similarly, a greater decline in the EQ-5D-3L visual analog scale score was observed with placebo (−6.9; 95% CI: −9.4 to −4.5) versus pembrolizumab (−2.7; 95% CI: −4.5 to −1.0; difference vs. placebo: 4.2; 95% CI: 1.2–7.2; nominal p= 0.0030). TTD in EORTC QLQ-C30 GHS/QoL score was similar between arms (hazard ratio, 0.85; 95% CI: 0.58–1.25; nominal p= 0.1993). Conclusion:Patients receiving placebo showed a greater decline in HRQoL than those receiving pembrolizumab. Combined with efficacy and safety data from KEYNOTE-394 and the global KEYNOTE-240 and KEYNOTE-224 trials, our data support the clinically meaningful benefit and manageable tolerability of pembrolizumab as second-line therapy for patients with advanced hepatocellular carcinoma.

Published
2023
Full Text
View/download PDF

68. Tunable NIR Absorption Property of a Dithiolene Nickel Complex: A Promising NIR-II Absorption Material for Photothermal Therapy

Author

Wei Huang, Kai Chen, Qingyuan Zhang, Xinyue Jiang, Qingming Shen, Pengfei Sun, Fang Weijia, Yan Chen, and Xu Wenjuan

Subjects
Materials science, Cell Survival, Infrared Rays, Photothermal Therapy, Biomedical Engineering, Nanoparticle, chemistry.chemical_element, Antineoplastic Agents, Biocompatible Materials, Biomaterials, Coordination Complexes, Nickel, Materials Testing, Humans, Sulfhydryl Compounds, Particle Size, Absorption (electromagnetic radiation), Cell Proliferation, Molecular Structure, business.industry, Biochemistry (medical), General Chemistry, Photothermal therapy, chemistry, Optoelectronics, Drug Screening Assays, Antitumor, business, HeLa Cells
Abstract

Exogenous photothermal agents absorbing in the second near-infrared optical window (NIR-II, 1000-1700 nm) have received much attention due to their use in noninvasive photothermal therapy. A small quantity of organic NIR-II photothermal agents have been exploited, and the development of organic NIR-II photothermal materials is an urgent need for biological applications. In this study, we designed and synthesized three dithiolene nickel(II) complexes with different ligands-bis(phenyl) dithiolene for NiBD-Ph, bis(fluorenyl) dithiolene for NiBD-Fl, and bis(carbazolyl) dithiolene for NiBD-Cz-and investigated their photophysical properties. These complexes exhibited ligand-dependent NIR absorption performance, centered at 854 nm for NiBD-Ph, 942 nm for NiBD-Fl, and 1010 nm for NiBD-Cz, respectively. NiBD-Cz is wrapped in ethylene oxide/propylene oxide block copolymer (F-127) through a hydrophilic-hydrophobic interaction to form water-soluble NiBD-Cz/F-127 nanoparticles (NiBD-Cz NPs), and the absorption peak of NiBD-Cz NPs are red-shifted to 1036 nm. NiBD-Cz NPs exhibit good dispersibility in water, robust photostability, and a high photothermal conversion efficiency (PCE) of 63.6% under 1064 nm laser irradiation, which is the highest PCE among metal bis(dithiolene) complexes up to now. The high PCE makes it possible to achieve better photothermal treatment effects even at low concentrations and under low-power laser irradiation.

Published
2021
Full Text
View/download PDF

70. Characterization of Genomic Alterations in Colorectal Liver Metastasis and Their Prognostic Value

Author

Bao, Xuanwen, primary, Wang, Kun, additional, Liu, Ming, additional, Li, Bin, additional, Wang, Hongwei, additional, Jin, Kemin, additional, Yan, Xiaoluan, additional, Zhang, Hangyu, additional, Bao, Quan, additional, Xu, Da, additional, Wang, Lijun, additional, Liu, Wei, additional, Wang, Yanyan, additional, Li, Juan, additional, Liu, Lijuan, additional, Fang, Weijia, additional, and Xing, Baocai, additional

Published
2022
Full Text
View/download PDF

71. Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

Author

Qin, Shukui, primary, Fang, Weijia, additional, Ren, ZhengGang, additional, Shuangyan, Ou, additional, Lim, Ho Yeong, additional, Zhang, Feng, additional, Choi, Hye Jin, additional, Tong, Jiandong, additional, Tao, Min, additional, Xu, Aibing, additional, Cheng, Ashley Chi Kin, additional, Lu, Chang-Hsien, additional, Chiu, Chang-Fang, additional, Wahid, Mohamed Ibrahim A., additional, Kamble, Shital, additional, Norquist, Josephine M., additional, Zhong, Wen Yan, additional, Li, Chen, additional, and Chen, Zhendong, additional

Published
2022
Full Text
View/download PDF

72. Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.

Author

Edeline, Julien, primary, Merle, Philippe, additional, Fang, Weijia, additional, Assenat, Eric, additional, Pan, Hongming, additional, Rimassa, Lorenza, additional, Li, Zhiwei, additional, Blanc, Jean-Frédéric, additional, Yen, Chia-Jui, additional, Ross, Paul J., additional, Hu, Sheng, additional, Zhang, Tao, additional, Tran, Albert, additional, Shao, Guoliang, additional, Bouattour, Mohamed, additional, Chen, Yajin, additional, Wu, John, additional, Li, Vincent, additional, Chica-Duque, Sandra, additional, and Ren, Zhenggang, additional

Published
2022
Full Text
View/download PDF

73. Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208.

Author

Cheng, Ann-Lii, primary, Hou, Jinlin, additional, Fang, Weijia, additional, Li, Zhiwei, additional, Hu, Sheng, additional, Pan, Hongming, additional, Chen, Yajin, additional, Hsu, Chiun, additional, Bai, Yuxian, additional, Meng, Zhiqiang, additional, Hou, Ming-Mo, additional, Xie, Congying, additional, Liu, Yong, additional, Li, Vincent, additional, Chica-Duque, Sandra, additional, Wu, John, additional, and Ren, Zhenggang, additional

Published
2022
Full Text
View/download PDF

74. Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma.

Author

Ren, Zhenggang, Shao, Guoliang, Shen, Jie, Zhang, Li, Zhu, Xu, Fang, Weijia, Sun, Guoping, Bai, Yuxian, Wu, Jianbing, Liu, Lianxin, Yuan, Yuan, Zhang, Jingdong, Li, Zhen, Zhang, Ling, Yin, Tao, Wu, Jincai, Hou, Xiaoli, Wang, Qingyu, Zhu, Jun, and Fan, Jia

Subjects
HEPATOCELLULAR carcinoma, BEVACIZUMAB, PROGRAMMED cell death 1 receptors, HEPATITIS associated antigen, GASTROINTESTINAL hemorrhage, POSTERIOR leukoencephalopathy syndrome, RENAL cell carcinoma
Abstract

Median duration of follow-up was 15.2 months (range, 2.0-17.8) in group A and 12.3 months (range, 1.7-16.2) in group B. Sixteen (80.0%) patients in group A and 16 (76.2%) patients in group B discontinued treatment, with PD being the main reason in both groups (Fig. The number of patients to be enrolled depended on observed toxicities; if treatment was considered well tolerated in the first 6 patients (or 12 patients if more evidence was required) during the 4-week observation period after the first dose, 20 patients were to be enrolled in each group. Among AESIs, irAEs occurred in 5 (25.0%) patients in group A and 8 (38.1%) patients in group B. Most irAEs were grade <=3; 2 (9.5%) patients in group B had grade 4 or 5 events of platelet count decrease. [Extracted from the article]

Published
2023
Full Text
View/download PDF

75. Dual targeted therapy with pyrotinib and trastuzumab for HER2‐positive advanced colorectal cancer: A phase 2 trial.

Author

Fu, Xianhua, Ying, Jieer, Yang, Liu, Fang, Weijia, Han, Weidong, Hu, Hanguang, Zhang, Suzhan, and Yuan, Ying

Abstract

This trial was initiated to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)‐positive recurrent/metastatic colorectal cancer (CRC). In this single‐arm, open‐label, multicenter, phase 2 trial patients with HER2‐positive recurrent/metastatic CRC were enrolled and received oral pyrotinib 400 mg once a day plus intravenous trastuzumab 8 mg/kg loading dose followed by 6 mg/kg once every 3 weeks. The primary endpoint was the objective response rate (ORR). Disease control rate (DCR), progression‐free survival (PFS), duration of response, and safety were assessed as secondary endpoints. From December 2019 to October 2021, a total of 20 patients were enrolled and 18 of them were evaluable for response. All patients were B‐rapidly accelerated fibrosarcoma (BRAF) wild type. Four patients achieved partial response, with an ORR of 22.2% (4/18, 95% confidence interval [CI] 6.4–47.6) and DCR of 61.1% (11/18, 95% CI 35.8–82.7), while the ORR and DCR were 33.3% (4/12, 95% CI 13.8–60.9) and 83.3% (10/12, 95% CI 51.6–97.9), respectively, in RAS wild‐type patients. At the time of cut‐off day, median follow‐up was 10.7 months (range 3.8–13.8). The median PFS was 3.4 months (95% CI 1.8–4.3) in the overall population and 4.3 months (95% CI 3.2–8.5) in the RAS wild‐type group. The most common adverse event of grade ≥3 was diarrhea (13/20, 65.0%). Pyrotinib combined with trastuzumab showed promising antitumor activity and a manageable safety profile in patients with RAS/BRAF wild‐type HER2‐positive advanced CRC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

78. Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing–Assisted Multiomics Analysis

Author

Bao, Xuanwen, primary, Li, Qiong, additional, Chen, Jinzhang, additional, Chen, Diyu, additional, Ye, Chanqi, additional, Dai, Xiaomeng, additional, Wang, Yanfang, additional, Li, Xin, additional, Rong, Xiaoxiang, additional, Cheng, Fei, additional, Jiang, Ming, additional, Zhu, Zheng, additional, Ding, Yongfeng, additional, Sun, Rui, additional, Liu, Chuan, additional, Huang, Lingling, additional, Jin, Yuzhi, additional, Li, Bin, additional, Lu, Juan, additional, Wu, Wei, additional, Guo, Yixuan, additional, Fu, Wenguang, additional, Langley, Sarah Raye, additional, Tano, Vincent, additional, Fang, Weijia, additional, Guo, Tiannan, additional, Sheng, Jianpeng, additional, Zhao, Peng, additional, and Ruan, Jian, additional

Published
2022
Full Text
View/download PDF

80. Case Report: Effectiveness of Targeted Treatment in a Patient With Pancreatic Cancer Harboring PALB2 Germline Mutation and KRAS Somatic Mutation

Author

Wu, Wei, Liu, Yu, Jin, Yuzhi, Liu, Lulu, Guo, Yixuan, Xu, Mian, Hao, Qing, Li, Dazhi, Fang, Weijia, Zhang, Aibin, and Zhao, Peng

Subjects
Medicine (General), R5-920, pancreatic cancer, KRAS somatic mutation, Medicine, case report, General Medicine, targeted therapy, PALB2 germline mutation
Abstract

Pancreatic cancer is one of the most leading causes of cancer death worldwide. The rapid development of next-generation sequencing (NGS) and precision medicine promote us to seek potential targets for the treatment of pancreatic cancer. Here, we report a female pancreatic cancer patient who underwent radical surgical excision after neoadjuvant chemotherapy. After the surgery, the patient underwent gemcitabine + S-1 therapy, capecitabine + albumin paclitaxel therapy and irinotecan therapy successively, however, MRI review revealed tumor progression. The surgical tissue sample was subjected to next-generation sequencing (NGS), and PALB2 germline mutation and KRAS somatic mutation were identified. The patient then received olaparib (a PARP inhibitor) + irinotecan and the disease stabilized for one year. Due to the increased CA19-9, treatment of the patient with a combination of trametinib (a MEK inhibitor) and hydroxychloroquine resulted in stable disease (SD) with a significant decrease of CA19-9. This case demonstrated that the NGS may be a reliable method for finding potential therapeutic targets for pancreatic cancer.

Published
2022
Full Text
View/download PDF

82. Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC).

Author

Zhang, Feng, primary, Bai, Yuxian, additional, Fang, Weijia, additional, Meng, Zhiqiang, additional, Xiong, Jianping, additional, Guo, Yabing, additional, Zhang, Tao, additional, Zhang, Jingdong, additional, Ying, Jieer, additional, Chen, Zhendong, additional, Ren, Zhenggang, additional, Chen, Yajin, additional, Hao, Chunyi, additional, Yang, Liu, additional, Wang, Jun, additional, Zhang, Juan, additional, Yu, Fan, additional, Fei, Cong, additional, Wu, Xikun, additional, and Qin, Shukui, additional

Published
2022
Full Text
View/download PDF

83. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

Author

Qin, Shukui, primary, Chen, Zhendong, additional, Fang, Weijia, additional, Ren, Zhenggang, additional, Xu, Ruocai, additional, Ryoo, Baek-Yeol, additional, Meng, Zhiqiang, additional, Bai, Yuxian, additional, Chen, Xiaoming, additional, Liu, Xiufeng, additional, Xiao, Juxiang, additional, Ho, Gwo Fuang, additional, Mao, Yimin, additional, Ye, Xing, additional, Ying, Jieer, additional, Li, Jianfeng, additional, Zhong, Wen Yan, additional, Zhou, Yu, additional, Siegel, Abby B., additional, and Hao, Chunyi, additional

Published
2022
Full Text
View/download PDF

85. NKG2D discriminates diverse ligands through selectively mechano‐regulated ligand conformational changes

Author

Fan, Juan, primary, Shi, Jiawei, additional, Zhang, Yong, additional, Liu, Junwei, additional, An, Chenyi, additional, Zhu, Huaying, additional, Wu, Peng, additional, Hu, Wei, additional, Qin, Rui, additional, Yao, Danmei, additional, Shou, Xin, additional, Xu, Yibing, additional, Tong, Zhou, additional, Wen, Xue, additional, Xu, Jianpo, additional, Zhang, Jin, additional, Fang, Weijia, additional, Lou, Jizhong, additional, Yin, Weiwei, additional, and Chen, Wei, additional

Published
2021
Full Text
View/download PDF

86. Improved Survival After Multidisciplinary Team Decision-Making for Patients with Advanced Gastrointestinal Cancer: A Multicenter, Prospective, Noninterventional, Controlled Study

Author

Zhang, Qi, primary, Zhou, Ye, additional, Song, Lijie, additional, Fang, Weijia, additional, Qiu, Meng, additional, Gu, Yanhong, additional, Yang, Yang, additional, Zhang, Jingdong, additional, Liu, Jing, additional, Lu, Ming, additional, Gong, Tianxiao, additional, Wang, Xin, additional, Li, Yan, additional, Yang, Jun, additional, Ye, Yingjiang, additional, Shen, Lin, additional, and Li, Jian, additional

Published
2021
Full Text
View/download PDF

88. Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized–controlled open-label Phase II study.

Author

Zhang, Hangyu, Tong, Zhou, Liu, Lulu, Fu, Qihan, Zhu, Xudong, Dai, Xiaomeng, Bao, Xuanwen, Fang, Weijia, Zheng, Yi, and Zhao, Peng

Subjects
IRINOTECAN, PANCREATIC cancer, CANCER patients, CANCER treatment, OXALIPLATIN
Abstract

Background Limited second-line therapeutic options are available for metastasis pancreatic cancer (mPC). We aimed to explore the efficacy and safety of oxaliplatin plus irinotecan (IROX) in mPC patients. Methods This is an open-label, Phase 2, randomized study of mPC patients (aged 18–75 years) who failed when using gemcitabine plus S-1 as first-line therapy. Block randomization with a block size of four was used to randomly assign patients (1:1) between October 2015 and December 2017 to receive either IROX (oxaliplatin 85 mg/m2 and irinotecan 160 mg/m2) or irinotecan monotherapy (irinotecan 180 mg/m2) until disease progression, unacceptable adverse events, or consent withdrawal. The primary end point was overall survival, and the secondary end points were progression-free survival, overall response rate, and adverse event rate. Results A total of 74 patients were enrolled in this study, including 44 males and 30 females, with an average age of 61 years. The median overall survival was 10.2 and 6.7 months (adjusted hazard ratio [HR], 0.7; 95% confidence interval [CI], 0.4–1.2; P  =   0.20) and the median progression-free survival was 5.1 and 2.3 months (adjusted HR, 0.4; 95% CI, 0.2–0.6; P <  0.01) in the IROX group and irinotecan group, respectively. The overall response rates were 18.4% (7/38) in the IROX group and 5.5% (2/36) in the irinotecan group (P  =   0.06). Grade 3–4 adverse events occurred in 34% (13/38) of patients in the IROX group and 19% (7/36) of patients in the irinotecan group (P  =   0.15). Conclusions IROX had no significant survival benefit over irinotecan monotherapy in our study. However, IROX reduced the risk of disease progression by 60%, with acceptable toxicity. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

89. Editorial: Immunotherapy in Hepatocellular Carcinoma

Author

Li, Bin, Lam, Ka-On, Lee, Victor Ho-Fun, and Fang, Weijia

Subjects
tumor immune microenvironment, Editorial, Oncology, liquid biopsy, gut microbiota, PD-1, hepatocellular carcinoma, immunotherapy
Published
2021

91. 412 CAMrelizumab and apatiniB combIned with chemoTherapy (mFOLFOX6) as neoadjuvant therapy for locally advanced rIght-sided colON cancer (AMBITION)

Author

Tong, Zhou, primary, Lu, Sen, additional, Dai, Xiaomeng, additional, Cheng, Xiaobin, additional, Bao, Xuanwen, additional, Zhu, Xudong, additional, Cheng, Xiaofei, additional, Fu, Qihan, additional, Wang, Danyang, additional, Zhang, Hangyu, additional, Sheng, Qinsong, additional, Liu, Lulu, additional, Zhang, Guoliang, additional, Zheng, Yi, additional, Liu, Fanlong, additional, Zhao, Peng, additional, Chen, Wenbin, additional, Fang, Weijia, additional, and Xu, Xiangmin, additional

Published
2021
Full Text
View/download PDF

95. Advantage of Next-Generation Sequencing in Dynamic Monitoring of Circulating Tumor DNA over Droplet Digital PCR in Cetuximab Treated Colorectal Cancer Patients1

Author

Zhang, Hangyu, Liu, Rujiao, Yan, Cong, Liu, Lulu, Tong, Zhou, Jiang, Weiqin, Yao, Ming, Fang, Weijia, and Chen, Zhiyu

Subjects
Original article
Abstract

Epidermal growth factor receptor (EGFR) blockade resistance is common in the treatment of RAS wide type colorectal cancer (CRC). During the treatment of cetuximab, acquired resistant genomic alterations always occurs earlier than disease progression observed by medical images. Identification of genomic alterations dynamically might have certain clinical significance. Because of the limitation of repeated tissue biopsy, liquid biopsy is increasingly recognized. Droplet digital polymerase chain reaction (ddPCR) is the main detection methods for circulating tumor DNA (ctDNA), however, the application of next-generation sequencing (NGS) for ctDNA detection becomes more and more popular. Here we develop a NGS-based ctDNA assay and evaluated its sensitivity and specificity while using ddPCR as control. These two technologies were both used for genomic alteration detection for the peripheral blood samples from cetuximab-treated colorectal cancer patients dynamically. Fifteen patients were enrolled in this study, including eight males and seven females. The sensitivity and specificity of our NGS assay were 87.5% and 100% respectively, and liner regression analysis comparing variant allele frequency (VAF) revealed high concordance between NGS and ddPCR (R2 = 0.98). NGS actually found more mutation information than ddPCR such as the additional dynamic changes of TP53 which were observed in the disease progression patients. Moreover, the variant allele fraction of TP53 was also found by NGS to be changed along with the clinical efficacy evaluation dynamically during the whole treatment process. In conclusion, our newly developed NGS-based ctDNA assay shows similar performance with ddPCR but have more advantages of its high throughput of multigenetic detection for the dynamic monitoring during the treatment of cetuximab in metastasis CRC patients.

Published
2018

97. Novel Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing-Assisted Multi-Omics Analysis

Author

Bao, Xuanwen, primary, Li, Qiong, additional, Chen, Jinzhang, additional, Chen, Diyu, additional, Ye, Chanqi, additional, Dai, Xiaomeng, additional, Wang, Yanfang, additional, Li, Xin, additional, Rong, Xiaoxiang, additional, Cheng, Fei, additional, Jiang, Ming, additional, Zhu, Zheng, additional, Ding, Yongfeng, additional, Sun, Rui, additional, Huang, Lingling, additional, Wu, Wei, additional, Guo, Yixuan, additional, Wu, Jiangchao, additional, Fu, Wenguang, additional, Tano, Vincent, additional, Fang, Weijia, additional, Guo, Tiannan, additional, Sheng, Jianpeng, additional, Zhao, Peng, additional, and Ruan, Jian, additional

Published
2021
Full Text
View/download PDF

98. GdClean: removal of Gadolinium contamination in mass cytometry data

Author

Liu, Junwei, primary, Liu, Lulu, additional, Qu, Saisi, additional, Zhang, Tongtong, additional, Wang, Danyang, additional, Ji, Qinghua, additional, Wang, Tian, additional, Shi, Hongyu, additional, Song, Kaichen, additional, Fang, Weijia, additional, Chen, Wei, additional, and Yin, Weiwei, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results